Home » Posts tagged 'Perfluorohexyloctane'
Tag Archives: Perfluorohexyloctane
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREFlag and hits
ORGANIC SPECTROSCOPY
SUBSCRIBE
Subscribe in a reader
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by Email
Recent Comments
 | shivkr2 on SPSR Excellence Award 2025 – S… |
 | Bonkasaurus on Infigratinib phosphate |
 | PALOVAROTENE | ORGAN… on Palovarotene |
| Pfizer just purchase… on Temanogrel | |
| Pfizer To Cash In On… on Temanogrel |
Perfluorhexyloctane
WeightAverage: 432.269
Monoisotopic: 432.112266666Chemical FormulaC14H17F13
Perfluorhexyloctane
- 133331-77-8
- MIEBO
- Tetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-
- 7VYX4ELWQM
- NOV03, NOV 03
- 1-(perfluorohexyl)octane
- F6H8
- NOV03
- Perfluorohexyloctane
1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane
FDA APPROVED 8/16/2023, Sohonos, To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva
Drug Trials Snapshot
Perfluorohexyloctane is a fluoroalkane that is tetradecane in which all of the hydrogen atoms at positions 1, 2, 3, 4, 5, and 6 have been replaced by fluorine atoms. It is an ophthalmic solution used to treat the signs and symptoms of dry eye disease. It has a role as an ophthalmology drug and a nonionic surfactant. It is a fluorohydrocarbon and a fluoroalkane. It derives from a hydride of a tetradecane.
Perfluorohexyloctane (branded as Evotears, Miebo,[a] and Novatears, among others) is a medication used for the treatment of dry eye disease.[4] It is a semifluorinated alkane.[4]
Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names Evotears and Novatears,[5] and was additionally approved for medical use in the United States in May 2023 under the brand name Miebo.[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]
PATENT
Show 102550100 entries
| Patent Number | Pediatric Extension | Approved | Expires (estimated) | |
|---|---|---|---|---|
| US11357738 | No | 2022-06-14 | 2036-09-29 |  |
| US10058615 | No | 2018-08-28 | 2033-09-12 | |
| US10369117 | No | 2019-08-06 | 2033-09-12 | |
| US10449164 | No | 2019-10-22 | 2033-09-12 | |
| US10507132 | No | 2019-12-17 | 2037-06-21 | |
| US10576154 | No | 2020-03-03 | 2033-09-12 | |
SYN
https://www.scientificupdate.com/process-chemistry-articles/not-a-dry-eye-in-the-house
Medical uses
Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.[4][8][9]
Availability
Perfluorohexyloctane is sold as an over-the-counter medication under the brand names Evotears and Novatears in multiple countries,[10] costing around NZ$34.00, A$30, and €30 for a one-month supply.
In the US, perfluorohexyloctane is sold under the brand name Miebo; a prescription is required.
Notes and references
- ^ “Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]”. Health Canada. 18 October 2024. Retrieved 25 October 2024.
- ^ “Miebo product information”. Health Canada. 4 September 2024. Retrieved 27 December 2024.
- ^ “Regulatory Decision Summary for Miebo”. Drug and Health Products Portal. 4 September 2024. Retrieved 27 December 2024.
- ^ Jump up to:a b c d e “Miebo- perfluorohexyloctane solution”. DailyMed. 18 May 2023. Retrieved 8 June 2023.
- ^ “URSAPHARM GmbH and Novaliq GmbH Announce European Partnership Agreement” (Press release). Retrieved 15 February 2024.
- ^ “Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease” (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023 – via Business Wire.
- ^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
- ^ Ballesteros-Sánchez A, De-Hita-Cantalejo C, Sánchez-González MC, Jansone-Langine Z, de Sotomayor MA, Culig J, et al. (October 2023). “Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent”. The Ocular Surface. 30: 254–262. doi:10.1016/j.jtos.2023.10.001. hdl:11441/151762. PMID 37813152. S2CID 263802332.
- ^ Sheppard JD, Evans DG, Protzko EE (November 2023). “A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution”. The American Journal of Managed Care. 29 (14 Suppl): S251 – S259. doi:10.37765/ajmc.2023.89464. PMID 37930231. S2CID 265032840.
- ^ “In Australia, NovaTears Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On” (Press release). Retrieved 15 February 2024.
Further reading
- Azhar A, Taimuri MA, Oduoye MO, Sumbal A, Sheikh A, Iqbal A, et al. (September 2024). “MEIBO (perfluorohexyloctane): a novel approach to treating dry eye disease”. Annals of Medicine and Surgery (2012). 86 (9): 5292–5298. doi:10.1097/MS9.0000000000002322. PMC 11374244. PMID 39239035.
| Clinical data | |
|---|---|
| Trade names | Evotears Miebo (/ˈmaɪboʊ/ MY-bow) Novatears |
| Other names | NOV03; 1-(perfluorohexyl)octane |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623054 |
| License data | US DailyMed: Perfluorohexyloctane |
| Routes of administration | Eye drops |
| ATC code | None |
| Legal status | |
| Legal status | CA: ℞-only[1][2][3]US: ℞-only[4] |
| Identifiers | |
| showIUPAC name | |
| CAS Number | 133331-77-8 |
| PubChem CID | 10477896 |
| DrugBank | DB17823 |
| ChemSpider | 8653305 |
| UNII | 7VYX4ELWQM |
| KEGG | D12604 |
| ChEBI | CHEBI:229658 |
| CompTox Dashboard (EPA) | DTXSID20440585 |
| Chemical and physical data | |
| Formula | C14H17F13 |
| Molar mass | 432.269 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| showSMILES | |
| showInChI | |
////////Perfluorhexyloctane, Sohonos, APPROVALS 2023, FDA 2023, NOV03, NOV 03, MIEBO, 1-perfluorohexyl)octane, F6H8, NOV03, Perfluorohexyloctane
New Drug Approvals 
